Ionis Pharmaceuticals (IONS) Total Current Liabilities (2009 - 2026)

Ionis Pharmaceuticals' Total Current Liabilities history runs 18 years deep, the most recent figure standing at $716.6 million for Q1 2026.

• On a quarterly basis, Total Current Liabilities rose 186.3% year-over-year to $716.6 million in Q1 2026; TTM through Mar 2026 was $716.6 million, a 186.3% increase from a year earlier, with the FY2025 full-year figure at $781.6 million, up 152.67% from the prior year.
• Total Current Liabilities slipped to $716.6 million in Q1 2026 per IONS's latest filing, from $781.6 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $903.5 million in Q3 2025 and bottomed at $228.4 million in Q1 2022.
• The 5-year median for Total Current Liabilities is $309.3 million (2024), against an average of $428.7 million.
• Across the five-year window, Total Current Liabilities slumped 30.97% in 2024 and soared 196.64% in 2025, its largest moves.
• Year by year, Total Current Liabilities stood at $311.6 million in 2022, then soared by 43.82% to $448.1 million in 2023, then slumped by 30.97% to $309.3 million in 2024, then surged by 152.67% to $781.6 million in 2025, then declined by 8.31% to $716.6 million in 2026.
• Per Business Quant, the three latest IONS Total Current Liabilities figures stand at $716.6 million (Q1 2026), $781.6 million (Q4 2025), and $903.5 million (Q3 2025).